• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma
CONCLUSIONS: TMZ-based SDT was capable of triggering ICD in glioma. The discovery of TMZ as a sonosensitizer have shown great promise in the treatment of GBM.PMID:37716612 | DOI:10.1016/j.clim.2023.109772
Source: Clinical Immunology - September 16, 2023 Category: Allergy & Immunology Authors: Yan Zhou Jiji Jiao Rongyan Yang Binli Wen Qiaoli Wu Lixia Xu Xiaoguang Tong Hua Yan Source Type: research

Toward a theranostic device for gliomas
CONCLUSIONS: We present an improved formulation of PVA-MBs to achieve a multifunctional device with adhesion ability, cytotoxicity on glioblastoma cells and supporting imaging.PMID:37300942 | DOI:10.1016/j.bbrc.2023.05.089
Source: Biochemical and Biophysical Research communications - June 10, 2023 Category: Biochemistry Authors: Gaio Paradossi Rachel Grossman Francesco Riccitelli Federica Todaro Zvi Ram Sara Schioppa Fabio Domenici Source Type: research

Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model
CONCLUSIONS: Olaparib effectively radiosensitises DMG cells in vitro and reduces primary tumour growth in vivo when combined with RT. Further studies are needed to investigate the therapeutic benefit of olaparib in suitable preclinical PDX models.PMID:37019285 | DOI:10.1016/j.jconrel.2023.03.058
Source: Cancer Control - April 5, 2023 Category: Cancer & Oncology Authors: E 't Hart J Bianco M A C Bruin M Derieppe H C Besse K Berkhout L A Chin Joe Kie Y Su E W Hoving A D R Huitema M G Ries D G van Vuurden Source Type: research

Polymer Nanocarriers for Targeted Local Delivery of Agents in Treating Brain Tumors
Nanotechnology. 2022 Sep 30. doi: 10.1088/1361-6528/ac9683. Online ahead of print.ABSTRACTGlioblastoma (GBM), the deadliest brain cancer, presents a multitude of challenges to the development of new therapies. The standard of care has only changed marginally in the past 17 years, and few new chemotherapies have emerged to supplant or effectively combine with temozolomide. Concurrently, new technologies and techniques are being investigated to overcome the pharmacokinetic challenges associated with brain delivery, such as the blood brain barrier (BBB), tissue penetration, diffusion, and clearance in order to allow for poten...
Source: Cancer Control - September 30, 2022 Category: Cancer & Oncology Authors: Alexander D Josowitz Ranjit S Bindra W Mark Saltzman Source Type: research